Biomedical Research
Additional Ventures Launches Single Ventricle SOURCE: A New Era of Single Ventricle Heart Disease Research
December 6, 2024
The future of single ventricle heart disease research is brighter than ever before, and today marks a historic milestone for the single ventricle community. Additional Ventures is proud to announce the launch of Single Ventricle SOURCE, a groundbreaking initiative that will transform our understanding of single ventricle heart disease and open new doors to innovative treatments and therapies.
Single Ventricle SOURCE is the largest and most ambitious study of its kind, aimed at uncovering the genetic causes behind single ventricle heart disease and its associated complications and comorbidities. SOURCE will enroll at least 5,000 single ventricle patients and 5,000 of their immediate family members (including birth parents, siblings, and children) to collect medical histories and genetic data through whole genome sequencing. Along with DNA samples, patients will also contribute their cardiac medical records, creating the world’s largest and most comprehensive genetic database for single ventricle heart disease.
Why SOURCE Matters: Unlocking Answers About Single Ventricle Heart Disease
The launch of Single Ventricle SOURCE represents a pivotal moment in the single ventricle research field. With SOURCE, researchers will have access to a robust genetic and clinical dataset that will enable them to answer critical, life-changing questions. Why do single ventricle heart defects occur? What genetic factors influence how the disease progresses? And why do some patients respond better to certain treatments than others?
This initiative is a game-changer for single ventricle research, providing the opportunity to unlock answers to questions that will help us develop better treatments and maybe even cures. By contributing their genetic and clinical data, patients and families will directly shape the future of research and help drive discoveries to improve care and outcomes.
Be the SOURCE of New Discoveries in Single Ventricle Heart Defect Research
SOURCE is open for enrollment today! Through a user-friendly online portal, participants can sign up from the comfort of their own homes using a computer or smartphone. A simple DNA collection kit, which includes a buccal swab, will be mailed directly to their door. With just a small sample, families will contribute to a massive movement that will advance scientific understanding of single ventricle heart disease.
In the near future, SOURCE will provide qualified researchers worldwide with free access to deidentified genetic and phenotypic data, fostering a collaborative, open research environment. This unprecedented access will empower scientists around the globe to explore new avenues of study and uncover the breakthroughs that will define the next generation of treatments.
The Promise of a New Era for Single Ventricle Research
The launch of Single Ventricle SOURCE represents hope for the future. With this study, Additional Ventures is igniting a new era of discovery that promises to redefine how we understand and treat single ventricle heart disease – a transformative step forward towards improving the lives of single ventricle patients. Together, we can make a difference.
Single Ventricle SOURCE is an IRB-approved study, funded by Additional Ventures.